目的：探讨人类内源性逆转录病毒-H长末端重复序列结合蛋白2（HHLA2）和其受体穿膜和免疫球蛋白结构域2（TMIGD2）在卵巢癌组织中的表达，分析其与卵巢癌患者临床病理特征及预后的关系。方法：通过免疫组织化学方法在包含154点/154例卵巢癌组织的芯片中分别检测HHLA2和其受体TMIGD2的表达，分析其表达水平与患者临床病理特征的关联性及其对预后的影响。结果：HHLA2的表达与卵巢癌病理分型有关（P<0.05）。Kaplan-Merier生存分析表明，在Ⅰ型卵巢癌中，HHLA2和TMIGD2高表达患者OS较短（P<0.05，P<0.01）。单因素Cox比例风险模型显示，卵巢癌Ⅱ型、FIGO分期Ⅲ和Ⅳ期、存在淋巴转移及远处转移者预后更差。多因素Cox风险模型分析显示，TMIGD2高表达、FIGO分期Ⅲ和Ⅳ期、存在淋巴转移、淋巴转移阳性可能是导致卵巢癌患者预后较差的独立影响因素，且HHLA2与TMIGD2表达呈正相关（r=0.603，P<0.01）。结论：HHLA2及其受体TMIGD2在卵巢癌组织中高表达且与患者的预后相关联，有望成为卵巢癌患者的预后预测指标。

Objective: To investigate the expression of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) and its receptor TMIGD2 (transmembrane and immunoglobulin domain containing 2) in ovarian cancer tissues and analyze the relationship between their expressions and the clinicopathological characteristics and prognosis of ovarian cancer patients.Methods: The expressions of HHLA2 and its receptor TMIGD2 were detected respectively by immunohistochemistry in a tissue microarray (TMA) containing 154 ovarian cancer tissues. The correlation between the expressions and the clinicopathological characteristics of the patients and the impact on prognosis were analyzed. Results: The expression of HHLA2 was associated with the pathological type of ovarian cancer (P<0.05). Kaplan-Merier survival analysis revealed that the high expression of HHLA2 and TMIGD2 was significantly correlated with poor OS in type Ⅰovarian cancer (P<0.05, P<0.01). Univariate Cox proportional hazard model indicated that type Ⅱ, FIGO stage Ⅲ and Ⅳ, lymphatic metastasis and distant metastasis were significantly associated with worse prognosis. Multivariate Cox proportional hazard model showed that TMIGD2 high expression, FIGO stage Ⅲ and Ⅳ, lymphatic metastasis, positive lymphatic metastasis may be independent influencing factors for poor prognosis of ovarian cancer patients and HHLA2 had significant positive correlation with TMIGD2 expression (r=0.603, P<0.01). Conclusion: HHLA2 and its receptor TMIGD2, which are highly expressed in ovarian cancer tissues and significantly correlated with the prognosis of patients, are expected to be prognostic indicators for ovarian cancer patients.

国家自然科学基金资助项目（No.81972869）；江苏省中医药科技发展计划专题研究项目（No. ZT202115）；江苏省重点研发计划专项 资金项目（No. BE2022719）；常州市社会发展科技支撑项目（No. CE20215030）；常州市科技计划项目（No. CJ20210158）